Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment

JAMA

Volumn 282, Issue 13, 1999, Pages 1240-1246

  Hayden, Frederick G ^a,b   Treanor, John J ^b   Fritz, R Scott ^b   Lobo, Monica ^b   Betts, Robert F ^b   Miller, Madeline ^b   Kinnersley, Nelson ^b   Mills, Roger G ^b   Ward, Penelope ^b   Straus, Stephen E ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; CYTOKINE; OSELTAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 0033530264     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.13.1240     Document Type: Article

References (39)

1. Liu C, Eichelberger MC, Compans RW, Air GM. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol. 1995;69:1099-1106.
2. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza JAMA 1996;275:295-299.
3. Burnet FM. Mucins and mucoids in relation to influenza virus action, III: inhibition of virus haemagglutination by glandular mucins. Aust J Exp Biol Med Sci. 1948;26:371-379.
4. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature. 1983;303:41-44.
5. Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 1994;3: 1687-1696.
6. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins. 1992;14:327-332.
7. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993;363:418-423.
8. Ryan DM, Ticehurst J, Dempsey MH, Penn CR. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother. 1994;38:2270-2275.
9. Ryan DM, Ticehurst J, Dempsey MH. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother. 1995;39:2583-2584.
10. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med. 1997;337:874-879.
11. MIST Study Group. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet. 1998;352:1877-1881.
12. Cass LMR, Efthymiopoubs C, Bye A. Pharmacokinetics of zanomivir after intravenous, oral inhaled, or intranasal administration to healthy volunteers. Clin Pharmacokinet. 1999;36(suppl):1-11.
13. Cass LMR, Brown J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanomivir in healthy volunteers. Clin Pharmacokinet. 1999;36(suppl):21-31.
14. Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc. 1997;119:681-690.
15. Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother. 1998;42:640-646.
16. Hayden FG, Rollins BS. In vitro activity of the neuraminidase inhibitor GS4071 against influenza viruses. Antiviral Res. 1997;34:A86.
17. Li W, Escarpe PA, Eisenberg EJ, et al. Identification of GS4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS4071. Antimicrob Agents Chemother. 1998;42:647-653.
18. Sidwell RW, Huffman JH, Barnard DL, et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res. 1998;37:107-120.
19. Kim CU, Bischofberger N, Williams MA, Lew W, Merson J, Sweet C. Efficacy of GS4104 in ferrets infected with influenza A virus. Antiviral Res. 1997;34:A74.
20. Eisenberg G, Bidgood A, Lynch G, Lee WA, Cundy K. Penetration of GS4071: a novel influenza neuraminidase inhibitor into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob Agents Chemother. 1997;41:1949-1952.
21. Wood ND, Aitken M, Sharp S, Evison H. Tolerability and pharmacokinetics of the influenza neuraminidase inhibitor Ro-64-0802 (GS4071) following oral administration of the prodrug Ro-64-0796 (GS4104) to healthy male volunteers. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1,1997; Toronto, Ontario. Abstract A-123.
22. Hayden FG, Tunkel AR, Treanor JJ, Betts RF, Allerheiligen S, Harris J. Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans. Antimicrob Agents Chemother. 1994;38: 1178-1181.
23. Walker JB, Hussey EK, Treanor JJ, Montalvo A, Hayden FG. Effects of the neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza. J Infect Dis. 1997;176:1417-1422.
24. Hayden FG, Fritz RS, Lobo M, Alvord G, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. J Clin Invest. 1998;101:643-649.
25. 2 in 2 × 2 contingency tables. J Am Stat Assoc. 1980;75:386-394.
26. Sears SD, Clements ML. Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus. Antimicrob Agents Chemother. 1987; 31:1470-1473.
27. 2 and B influenza. JAMA. 1970;213:1448-1454.
28. Reuman PD, Bernstein DI, Keefer MC, Young EC, Sherwood JR, Schiff GM. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res. 1989;11:27-40.
29. Jackson GG, Muldoon RL, Akers LW. Serological evidence for prevention of influenzal infection in volunteers by an anti-influenzal drug adamantanamine hydrochloride. Antimicrob Agents Chemother. 1963;3: 703-707
30. Dawkins ATJ, Gallager LR, Togo Y, Hornick RB, Harris BA. Studies on induced influenza in man, II: double-blind study designed to assess the prophylactic efficacy of an analogue of amantadine hydrochloride. JAMA. 1968;203:1095-1099.
31. Hayden FG, Zlydnikov DM, Iljenko VI, Padolka YV. Comparative therapeutic effect of aerosolized and oral rimantadine HCl in experimental human influenza A virus infection. Antiviral Res. 1982;2:147-153.
32. Hayden FG, Monto AS. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother. 1986;29:339-341.
33. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother. 1991;35:1741-1747.
34. Togo Y, Hornick RB, Felitti VJ, et al. Evaluation of therapeutic efficacy of amantadine in patients with naturally occurring A2 influenza. JAMA. 1970:211: 1149-1156.
35. VanVoris LP, Betts RF, Hayden FG, Christmas WA, Douglas RGJ. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA. 1981; 245:1128-1131.
36. Douglas RGJ. Prophylaxis and treatment of influenza. N Engl J Med. 1990;322:443-450.
37. Hayden FG, Atmar RL, Schilling M, et al. Safety and efficacy of oral GS4104 in long-term prophylaxis of natural influenza. In: Final Program, Abstracts and Exhibits Addendum: 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998; San Diego, Calif. Abstract LB-6.
38. Treanor JJ, Vrooman PS, Hayden FG, Kinnersley N, Ward P, Mills RG. Efficacy of oral GS4104 in treating acute influenza. In: Final Program, Abstracts and Exhibits Addendum: 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998; San Diego, Calif. Abstract LB-4.
39. Aoki FY, Osterhaus AD, Rimmelzwaan GF, Kinnersley N, Ward P. Oral GS4104 successfully reduces duration and severity of naturally acquired influenza. In: Final Program, Abstracts and Exhibits Addendum: 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998; San Diego, Calif. Abstract LB-5.